Skip to content
DataLookout
Menu

XYRISENCT07625280

A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 15 → 27 locations
  2. Notable Eligibility criteria expanded, about 33 words
    • Trial sites expanded: 3 → 15 locations
    • Secondary endpoints: details revised at 12 of 18 entries
  3. Notable Recruitment openedv2 Show 7 more changesShow less
    • Eligibility criteria expanded, about 125 words
    • Enrollment increased: 108 → 120 participants
    • Trial arms changed: 4 → 8
    • Study sites: 1 to 3
    • Start date changed from estimate of Jun 30, 2026 to Jul 9, 2026
    • Secondary endpoints: 7 to 18
    • Study description expanded, about 18 words
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Epworth Sleepiness Scale (ESS) scores
Timeframe: End of Stable Dose Period (up to Week 14), up to end of Double-Blind Randomized-Withdrawal Period (up to Week 16)

Secondary (18)

Percentage of participants reporting minimally, much and very much worse in their CGIc questionnaire for IH or narcolepsy symptoms
Percentage of participants reporting minimally, much and very much worse in their PGIc questionnaire for IH or narcolepsy symptoms
Change in IHSS scores in participants with IH
Change in weekly rate of cataplexy (WRC) in participants with NT1
Percentage of participants reporting minimally, much and very much worse in their PGIc questionnaire for sleepiness
Show 13 moreShow less
Change in Clinical Global Impression of Severity (CGIs) Scores for Narcolepsy/IH symptoms
Change in Patient Global Impression of Severity (PGIs) Scores for Narcolepsy/IH symptoms
Change in Patient Global Impression of Severity (PGIs) Scores for sleepiness
Change in NSS scores in participants with NT1
Change in NSS-2 scores in participants with NT2
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs)
Change in average total sleep time
Change in average sleep latency
Change in average wake after sleep onset (WASO)
Change in average number of awakenings after sleep onset (NAASO)
Sleep quality
Sleep episode frequency
Difficulty maintaining wakefulness

Arms and interventions

Narcolepsy Cohort once-nightly expanded Xywav dose groupActive comparator

Participants with narcolepsy will receive an expanded once-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will continue taking their stable dose of Xywav for 2 additional weeks.

Narcolepsy Cohort once-nightly expanded Xywav followed by placebo groupPlacebo comparator

Participants with narcolepsy will receive an expanded once-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will take placebo for 2 additional weeks.

Narcolepsy Cohort twice-nightly expanded Xywav dose groupActive comparator

Participants with narcolepsy will receive an expanded twice-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will continue taking their stable dose of Xywav for 2 additional weeks.

Narcolepsy Cohort twice-nightly expanded Xywav followed by placebo groupPlacebo comparator

Participants with narcolepsy will receive an expanded twice-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will take placebo for 2 additional weeks.

IH Cohort once-nightly expanded Xywav dose groupActive comparator

Participants with IH will receive an expanded once-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will continue taking their stable dose of Xywav for 2 additional weeks.

IH Cohort once-nightly expanded Xywav followed by placebo groupPlacebo comparator

Participants with IH will receive an expanded once-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will take placebo for 2 additional weeks.

IH Cohort twice-nightly expanded Xywav dose groupActive comparator

Participants with IH will receive an expanded twice-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will continue taking their stable dose of Xywav for 2 additional weeks.

IH Cohort twice-nightly expanded Xywav followed by placebo groupPlacebo comparator

Participants with IH will receive an expanded twice-nightly dosing of Xywav for up to 14 weeks until they reach a stable dose. Once stable dose is achieved, participants will take placebo for 2 additional weeks.

Drugs: Xywav

Other: Placebo

Sites

27 sites in 1 country